InterCure Ltd. Fundamental Analysis (NASDAQ: INCR)
InterCure Ltd. Fundamental Analysis (NASDAQ: INCR)
InterCure Ltd. (NASDAQ: INCR) shows moderate financial fundamentals with a PE ratio of -3.56, profit margin of -16.99%, and ROE of -8.54%. The company generates $0.3B in annual revenue with strong year-over-year growth of 13.13%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 17.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze INCR's fundamental strength across five key dimensions:
Efficiency Score
WeakINCR struggles to generate sufficient returns from assets.
Valuation Score
ExcellentINCR trades at attractive valuation levels.
Growth Score
ExcellentINCR delivers strong and consistent growth momentum.
Financial Health Score
ExcellentINCR maintains a strong and stable balance sheet.
Profitability Score
WeakINCR struggles to sustain strong margins.
Key Financial Metrics
Is INCR Expensive or Cheap?
P/E Ratio
INCR trades at -3.56 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, INCR's PEG of -0.02 indicates potential undervaluation.
Price to Book
The market values InterCure Ltd. at 0.32 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -0.40 times EBITDA. This is generally considered low.
How Well Does INCR Make Money?
Net Profit Margin
For every $100 in sales, InterCure Ltd. keeps $-16.99 as profit after all expenses.
Operating Margin
Core operations generate -14.67 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-8.54 in profit for every $100 of shareholder equity.
ROA
InterCure Ltd. generates $-5.05 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
InterCure Ltd. produces operating cash flow of $32.33M, showing steady but balanced cash generation.
Free Cash Flow
InterCure Ltd. produces free cash flow of $25.52M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $1.97 in free cash annually.
FCF Yield
INCR converts 12.40% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-3.56
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.02
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.32
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.78
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.46
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.48
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.09
vs 25 benchmark
ROA
Return on assets percentage
-0.05
vs 25 benchmark
ROCE
Return on capital employed
-0.06
vs 25 benchmark
How INCR Stacks Against Its Sector Peers
| Metric | INCR Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -3.56 | 31.66 | Better (Cheaper) |
| ROE | -8.54% | 501.00% | Weak |
| Net Margin | -16.99% | -3647.00% (disorted) | Weak |
| Debt/Equity | 0.46 | -0.30 (disorted) | Distorted |
| Current Ratio | 1.48 | 5.78 | Neutral |
| ROA | -5.05% | -262.00% (disorted) | Weak |
INCR outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews InterCure Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
85.76%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
57.12%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-3.50%
Industry Style: Defensive, Growth, Innovation
Declining